Thus, CD73 can affect the efficiency of EGFR-targeted therapies via miR-30a-5p in wild-type EGFR in NSCLC cells; yet, further studies are still needed to explore the underlying mechanisms of CD73-mediated drug resistance to improve the NSCLC treatment [70]. Here, EGFR is linked to non-small cell lung carcinoma.